APA (7th ed.) Citation

Loibl, S., Sikov, W., Huober, J., Rugo, H., Wolmark, N., O'Shaughnessy, J., . . . Geyer, C. (2021). 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial. Annals of Oncology, 32, S408. https://doi.org/10.1016/j.annonc.2021.08.400

Chicago Style (17th ed.) Citation

Loibl, S., et al. "119O Event-free Survival (EFS), Overall Survival (OS), and Safety of Adding Veliparib (V) Plus Carboplatin (Cb) or Carboplatin Alone to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer (TNBC) After ≥4 Years of Follow-up: BrighTNess, a Randomized Phase III Trial." Annals of Oncology 32 (2021): S408. https://doi.org/10.1016/j.annonc.2021.08.400.

MLA (9th ed.) Citation

Loibl, S., et al. "119O Event-free Survival (EFS), Overall Survival (OS), and Safety of Adding Veliparib (V) Plus Carboplatin (Cb) or Carboplatin Alone to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer (TNBC) After ≥4 Years of Follow-up: BrighTNess, a Randomized Phase III Trial." Annals of Oncology, vol. 32, 2021, p. S408, https://doi.org/10.1016/j.annonc.2021.08.400.